Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers

por Freis, Patricia, Graillot, Emmanuelle, Rousset, Pascal, Hervieu, Valérie, Chardon, Laurence, Lombard-Bohas, Catherine, Walter, Thomas
Publicado 2017

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma

por Couronne, Thomas, Girot, Paul, Hadoux, Julien, Lecomte, Thierry, Durand, Alice, Fine, Caroline, Vandevoorde, Katia, Lombard-Bohas, Catherine, Walter, Thomas
Publicado 2020

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial

por Lombard-Bohas, Catherine, Yao, James C., Hobday, Timothy, Van Cutsem, Eric, Wolin, Edward M., Panneerselvam, Ashok, Stergiopoulos, Sotirios, Shah, Manisha H., Capdevila, Jaume, Pommier, Rodney
Publicado 2015

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with...

por Lamarca, Angela, Barriuso, Jorge, Kulke, Matthew, Borbath, Ivan, Lenz, Heinz-Josef, Raoul, Jean Luc, Meropol, Neal J, Lombard-Bohas, Catherine, Posey, James, Faivre, Sandrine, Raymond, Eric, Valle, Juan W
Publicado 2018

Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence

por Morin, Carole, Benedetto, Keo-Morakort, Deville, Agathe, Milot, Laurent, Theillaumas, Aurélie, Hervieu, Valérie, Pioche, Mathieu, Poncet, Gilles, Forestier, Julien, François, Laurent, Borson-Chazot, Francoise, Adham, Mustapha, Lombard-Bohas, Catherine, Walter, Thomas
Publicado 2022

Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tu...

por Smith, Denis, Lepage, Côme, Vicaut, Eric, Dominguez, Sophie, Coriat, Romain, Dubreuil, Olivier, Lecomte, Thierry, Baudin, Eric, Venat Bouvet, Laurence, Samalin, Emmanuelle, Santos, Alexandre, Borie, Odile, Bisot-Locard, Ségolène, Goichot, Bernard, Lombard-Bohas, Catherine
Publicado 2022

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors

por Salazar, Ramon, Garcia‐Carbonero, Rocio, Libutti, Steven K., Hendifar, Andrew E., Custodio, Ana, Guimbaud, Rosine, Lombard‐Bohas, Catherine, Ricci, Sergio, Klümpen, Heinz‐Josef, Capdevila, Jaume, Reed, Nicholas, Walenkamp, Annemiek, Grande, Enrique, Safina, Sufiya, Meyer, Tim, Kong, Oliver, Salomon, Herve, Tavorath, Ranjana, Yao, James C.
Publicado 2017

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

por Niogret, Julie, Limagne, Emeric, Thibaudin, Marion, Blanc, Julie, Bertaut, Aurelie, Le Malicot, Karine, Rinaldi, Yves, Caroli-Bosc, François-Xavier, Audemar, Franck, Nguyen, Suzanne, Sarda, Corinne, Lombard-Bohas, Catherine, Locher, Christophe, Carreiro, Miguel, Legoux, Jean-Louis, Etienne, Pierre-Luc, Baconnier, Mathieu, Porneuf, Marc, Aparicio, Thomas, Ghiringhelli, Francois
Publicado 2020